Roche, United States of America. Following the publication of the results of a review reporting 60 cases of thrombotic thrombocytopenic purpura associated with the use of the platelet aggregation inhibitor, ticlopidine (Ticlid), the manufacturer has revised the package insert to include a boxed warning about this reaction and the relevant sections of the product information have been revised accordingly.

[See Pharmaceuticals Newsletter Nos. 5&6, May & June 1998; Nos 9&10, September & October 1997 and No. 2, February 1996]

Reference: “Dear Doctor” letter, Roche Laboratories Inc. [http://www.fda.gov/medwatch/safety/1998/ticlid2.htm]